Article

Surgeons weigh WFG ablation

Leading refractive surgeons agree wavefront-guided ablation is a significant advance in laser vision correction, but have different opinions about its role in treating myopic eyes with low higher-order aberrations.

Orlando-Leading refractive surgeons agree wavefront-guided (WFG) ablation is a significant advance in laser vision correction, but have different opinions about its role in treating myopic eyes with low higher-order aberrations (HOAs).

Ronald Krueger, MD, explained why he believes WFG ablation has no measurable advantage in these cases, defined as having total HOA RMS < 0.3 μm. Steven C. Schallhorn, MD, presented evidence supporting its use.

Dr. Krueger, medical director, refractive surgery, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, noted that the outcomes of a WFG treatment depend strongly on having a reliable wavefront measurement, perfect centration, and perfect eye-tracker performance. However, cyclorotation of more than 2° can occur in about two-thirds of patients and failure of iris recognition and iris tracking are also relatively common.

Both of these issues make perfect centration difficult, Dr. Krueger said.

He also presented data from a study he performed using adaptive optics that showed HOA < 0.3 μm are not visually significant along with evidence that for ideal visual performance, HOAs, should be optimized to maintain a prolate cornea, rather than minimized. This latter outcome can be achieved with a wavefront-optimized (WFO) ablation profile.

Finally, results of multiple comparative studies as well as a recent meta-analysis including 930 eyes from seven studies show no differences in refractive and visual acuity outcomes comparing groups of eyes with low levels of HOA undergoing WFG versus WFO ablation.

“These papers found that WFG is important in eyes with more than 0.3 μm HOA, but it has no benefit over WFO for the myopic eye with HOA < 0.3 μm,” Dr. Krueger said. “In fact, in eyes treated for higher levels of myopia, there is some induction of spherical aberration, especially when the profile is not WFO. Therefore, I believe WFO should be used in eyes with low HOAs, and specifically in higher myopes.”

In his discussion, Dr. Schallhorn, global medical director, Optical Express, presented study data showing that differences can be detected favoring WFG versus WFO ablation in eyes with low levels of HOA. For example, in a study by Tanzer et al. that evaluated a number of different endpoints, differences were found in very fine levels of uncorrected visual acuity (UCVA), mesopic 25% contrast acuity, and induction of HOA. Manche et al. also reported that at 12 months, WFG treatment was associated with better 25% mesopic contrast acuity, better UCVA, and greater patient preference than WFO ablation.

“The WFG treatment induces less HOA than WFO ablation and that gives advantages,” Dr. Schallhorn said. “Granted, they are subtle and may not show up in refractive outcomes or even in UCVA. However, they are detected in more sensitive measures of visual function, such as contrast sensitivity, or what I collectively call quality of vision.”

For more articles in this issue of Ophthalmology Times Conference Brief click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.